VolitionRx is betting that simple blood tests can help spot cancer and immune-related illnesses earlier, with both human and veterinary products starting to move from trials into real-world use. The upside hinges on big partners turning pilots into routine testing, but delays, limited insurance coverage, or stronger rivals could keep growth stuck in the early stage.Read more
A small diagnostics company is trying to turn its blood-test platform into a bigger business by teaming up with major lab players and expanding into everyday vet screening. The upside hinges on whether these partnerships translate into routine hospital and clinic use before funding needs and competition slow the rollout.Read more
VolitionRx is trying to turn its blood-based tests into real-world products, but progress may stay bumpy as it relies on partners, long studies, and slow-moving approvals. The upside rests on wider demand for earlier cancer detection and new blood-testing approaches, yet delays or missed deals could keep results from showing up for a while.Read more
No trending discussion available.
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
